Surveillance epidemiology and end results program (seer)- independent disclosure risk evaluation of the seer research databases
Ended Awarded
- Contract number
- 75N91021F00002
- Awardee
-
Westat, Inc. UEI NVUWAFWQ57S5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $149,859
Award facts
- Contract value 100% obligated
- $149,859.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541611 Administrative Management and General Management Consulting Services
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Rockville, MD 20850, USA
- Legislative mandates
-
- Clinger-Cohen Act FAR part 39
- Economy Act FAR subpart 17.5
Award details come from SAM.gov/FPDS.
About this award
The National Cancer Institute awarded Westat, Inc. a $149,859 firm fixed-price contract on June 7, 2021, to provide professional support for cancer surveillance activities under the Surveillance Epidemiology and End Results (SEER) Program. Specifically, the work involves an independent disclosure risk evaluation of the SEER research databases. This contract was awarded as a call under a Multiple Award Schedule (MAS) blanket purchase agreement (BPA) and was completed on June 30, 2022. No small business set-aside was used for this award.
Westat, a prominent research and technical services firm headquartered in Rockville, Maryland, is well-positioned to execute this work given its extensive experience supporting federal health agencies. The company specializes in data collection, analysis, statistical research, and program evaluation services, with a robust track record of delivering similar projects for the National Institutes of Health, Centers for Disease Control and Prevention, and other health-focused government entities. The SEER Program's cancer surveillance databases are critical national resources for cancer research and epidemiology, and this evaluation work ensures the integrity and confidentiality protections of these sensitive research datasets.
Quick answers
Who was awarded contract 75N91021F00002?
75N91021F00002 was awarded to Westat, Inc. by National Cancer Institute (National Institutes of Health) on June 7, 2021.
How much is contract 75N91021F00002 worth?
The government has obligated $149,859 on 75N91021F00002.
Is contract 75N91021F00002 an order under another contract?
Yes. 75N91021F00002 is a BPA call under GS00F009DA-HHSN261201600004B, a blanket purchase agreement, on Multiple Award Schedule (MAS).
Was contract 75N91021F00002 competed?
The extent of competition for 75N91021F00002 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award